SCHEMBL10208294

SCHEMBL10208294

CC(C)C[C@H](NP(=O)(Cl)Oc1cccc2ccccc12)C(=O)OCC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 1/20 0.41
ANPEP P15144 2/20 0.39
HTT P42858 1/20 0.38
CASP1 P29466 2/20 0.38
CASP3 P42574 2/20 0.38
CASP7 P55210 2/20 0.38
CASP6 P55212 2/20 0.38
CASP8 Q14790 2/20 0.38
BTN3A1 O00481 2/20 0.38
ALDH1A1 P00352 3/20 0.38
HSD17B10 Q99714 2/20 0.38
KDM4E B2RXH2 1/20 0.38
PSMB5 P28074 1/20 0.37
NTSR1 P30989 1/20 0.37
THRB P10828 1/20 0.36
HPGD P15428 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CNR2 P34972 1/20 0.36
OGG1 O15527 1/20 0.36
PGR P06401 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1743835 0.87 HTT (0.41) HTTBTN3A1ALDH1A1HSD17B10KDM4E
SCHEMBL723907 0.87 HTT (0.41) HTTBTN3A1ALDH1A1HSD17B10KDM4E
SCHEMBL10208172 0.87 HTT (0.41) HTTBTN3A1ALDH1A1HSD17B10KDM4E
SCHEMBL15837460 0.87 HTT (0.41) HTTBTN3A1ALDH1A1HSD17B10KDM4E
SCHEMBL724231 0.86 BCL2L1 (0.48) BCL2L1ANPEPCASP1CASP3CASP7
SCHEMBL10208250 0.85 CASP3 (0.40) HTTCASP3BTN3A1ALDH1A1HSD17B10
SCHEMBL28459943 0.85 CNR1 (0.41) BCL2L1ANPEPCASP1CASP3CASP7
SCHEMBL29708064 0.85 CNR1 (0.41) BCL2L1ANPEPCASP1CASP3CASP7
SCHEMBL28459946 0.85 CNR1 (0.41) BCL2L1ANPEPCASP1CASP3CASP7
SCHEMBL10208291 0.85 BTN3A1 (0.36) HTTBTN3A1ALDH1A1HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759318-B2 Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections INHIBITEX, INC. (US) 2014-06-24 US disclosed
US-8759318-B2 Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections INHIBITEX, INC. (US) 2014-06-24 US disclosed
US-20120052046-A1 Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2012-03-01 US disclosed
US-20120052046-A1 Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2012-03-01 US disclosed
WO-2010081082-A2 PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120052046-A1 Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections PNP, SAMHD1, MTAP BCL2L1 4172/4885ANPEP 583/4885HTT 2589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.